Tags

Type your tag names separated by a space and hit enter

Improved immunogenicity and protective efficacy of a divalent DNA vaccine encoding Brucella L7/L12-truncated Omp31 fusion protein by a DNA priming and protein boosting regimen.
Mol Immunol 2015; 66(2):384-91MI

Abstract

Brucellosis is one of the most common zoonotic diseases caused by species of Brucella. At present, there is no commercially available vaccine for the human brucellosis. Brucella melitensis and Brucella abortus are the main causes of human brucellosis, worldwide. The outer membrane protein 31 (Omp31) and L7/L12 are immunodominant and protective antigens conserved among human Brucella pathogens. The purpose of the current study was to evaluate and compare the immunogenicity and protective efficacy of the L7/L12-TOmp31 construct administered as DNA/DNA and DNA/Pro vaccine regimens. Vaccination of BALB/c mice with the DNA/Pro regimen provided more protection levels against B. melitenisis and B. abortus challenge than did the DNA/DNA regimen. IgG1 and IgG2a titers were higher in the sera from DNA/Pro-immunized mice than in those from mice immunized with DNA alone. Moreover, splenocytes from DNA/Pro-immunized mice produced significantly higher levels of IFN-γ than did those from mice given DNA alone. The pcDNA-L7/L12-TOmp31 priming followed by rL7/L12-TOmp31 boosting led to improved protection against B. abortus or B. melitensis infection.

Authors+Show Affiliations

Department of Molecular Biology, Pasteur Institute of Iran, Pasteur Street, Tehran, Iran.Department of Molecular Immunology and Vaccine Research, Pasteur Institute of Iran, Pasteur Street, Tehran, Iran. Electronic address: s_rafati@yahoo.com.Department of Bacteriology, Pasteur Institute of Iran, Pasteur Street, Tehran, Iran.Department of Bacterial Vaccine and Antigen Production, Pasteur Institute of Iran, Karaj, Iran.Department of Bacteriology, Pasteur Institute of Iran, Pasteur Street, Tehran, Iran.Department of Bacteriology, Pasteur Institute of Iran, Pasteur Street, Tehran, Iran.Department of Molecular Biology, Pasteur Institute of Iran, Pasteur Street, Tehran, Iran. Electronic address: saeidbouzari@yahoo.com.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25968974

Citation

Golshani, Maryam, et al. "Improved Immunogenicity and Protective Efficacy of a Divalent DNA Vaccine Encoding Brucella L7/L12-truncated Omp31 Fusion Protein By a DNA Priming and Protein Boosting Regimen." Molecular Immunology, vol. 66, no. 2, 2015, pp. 384-91.
Golshani M, Rafati S, Siadat SD, et al. Improved immunogenicity and protective efficacy of a divalent DNA vaccine encoding Brucella L7/L12-truncated Omp31 fusion protein by a DNA priming and protein boosting regimen. Mol Immunol. 2015;66(2):384-91.
Golshani, M., Rafati, S., Siadat, S. D., Nejati-Moheimani, M., Shahcheraghi, F., Arsang, A., & Bouzari, S. (2015). Improved immunogenicity and protective efficacy of a divalent DNA vaccine encoding Brucella L7/L12-truncated Omp31 fusion protein by a DNA priming and protein boosting regimen. Molecular Immunology, 66(2), pp. 384-91. doi:10.1016/j.molimm.2015.04.015.
Golshani M, et al. Improved Immunogenicity and Protective Efficacy of a Divalent DNA Vaccine Encoding Brucella L7/L12-truncated Omp31 Fusion Protein By a DNA Priming and Protein Boosting Regimen. Mol Immunol. 2015;66(2):384-91. PubMed PMID: 25968974.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Improved immunogenicity and protective efficacy of a divalent DNA vaccine encoding Brucella L7/L12-truncated Omp31 fusion protein by a DNA priming and protein boosting regimen. AU - Golshani,Maryam, AU - Rafati,Sima, AU - Siadat,Seyed Davar, AU - Nejati-Moheimani,Mehdi, AU - Shahcheraghi,Fereshteh, AU - Arsang,Amin, AU - Bouzari,Saeid, Y1 - 2015/05/18/ PY - 2015/03/06/received PY - 2015/04/20/revised PY - 2015/04/22/accepted PY - 2015/5/14/entrez PY - 2015/5/15/pubmed PY - 2015/8/12/medline KW - Brucella KW - DNA vaccine KW - Electroporation KW - Footpad route KW - Prime-boost strategy SP - 384 EP - 91 JF - Molecular immunology JO - Mol. Immunol. VL - 66 IS - 2 N2 - Brucellosis is one of the most common zoonotic diseases caused by species of Brucella. At present, there is no commercially available vaccine for the human brucellosis. Brucella melitensis and Brucella abortus are the main causes of human brucellosis, worldwide. The outer membrane protein 31 (Omp31) and L7/L12 are immunodominant and protective antigens conserved among human Brucella pathogens. The purpose of the current study was to evaluate and compare the immunogenicity and protective efficacy of the L7/L12-TOmp31 construct administered as DNA/DNA and DNA/Pro vaccine regimens. Vaccination of BALB/c mice with the DNA/Pro regimen provided more protection levels against B. melitenisis and B. abortus challenge than did the DNA/DNA regimen. IgG1 and IgG2a titers were higher in the sera from DNA/Pro-immunized mice than in those from mice immunized with DNA alone. Moreover, splenocytes from DNA/Pro-immunized mice produced significantly higher levels of IFN-γ than did those from mice given DNA alone. The pcDNA-L7/L12-TOmp31 priming followed by rL7/L12-TOmp31 boosting led to improved protection against B. abortus or B. melitensis infection. SN - 1872-9142 UR - https://www.unboundmedicine.com/medline/citation/25968974/Improved_immunogenicity_and_protective_efficacy_of_a_divalent_DNA_vaccine_encoding_Brucella_L7/L12_truncated_Omp31_fusion_protein_by_a_DNA_priming_and_protein_boosting_regimen_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0161-5890(15)00374-0 DB - PRIME DP - Unbound Medicine ER -